1. Home
  2. NEN vs GLSI Comparison

NEN vs GLSI Comparison

Compare NEN & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

NEN

New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

N/A

Current Price

$44.00

Market Cap

197.0M

Sector

Real Estate

ML Signal

N/A

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

N/A

Current Price

$15.03

Market Cap

236.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEN
GLSI
Founded
1977
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Building operators
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
197.0M
236.2M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
NEN
GLSI
Price
$44.00
$15.03
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $57.00
AVG Volume (30 Days)
1.2K
★ 118.2K
Earning Date
11-13-2026
11-24-2026
Dividend Yield
★ 3.61%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $89,196,544.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.68
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.24
$7.78
52 Week High
$71.07
$34.10

Technical Indicators

Market Signals
Indicator
NEN
GLSI
Relative Strength Index (RSI) 32.93 43.14
Support Level N/A $14.38
Resistance Level $66.30 $19.82
Average True Range (ATR) 0.63 1.40
MACD -0.06 -0.14
Stochastic Oscillator 0.00 15.18

Price Performance

Historical Comparison
NEN
GLSI

About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Share on Social Networks: